

Applicants: Novak et al.

Serial No.: 10/659,684

Filed: September 10, 2003

For: CYTOKINE ZALPHA11 LIGAND

Amendments to the Claims:

Per 37 C.F.R. §1.121, the current status of all the claims in the present application is presented below, amended claims are notated to indicate changes made and the text of pending claims not being amended are presented without notation.

Amendments to the following are indicated by underlining what has been added and striking-through what has been deleted.

Listing of Claims:

1. (original) An isolated polypeptide comprising a sequence of amino acid residues that is at least 90% identical to residues 41 (Gln) to 148 (Ile) as shown in SEQ ID NO:2.

2. (original) An isolated polypeptide comprising a sequence of amino acid residues that is at least 95% identical to residues 41 (Gln) to 148 (Ile) as shown in SEQ ID NO:2.

3. (original) An isolated polypeptide comprising a sequence of amino acid residues that is identical to residues 41 (Gln) to 148 (Ile) as shown in SEQ ID NO:2.

4. (canceled)

5. (original) An isolated polypeptide comprising a sequence of amino acid residues that is at least 90% identical to residues 32 (Gln) to 148 (Ile) as shown in SEQ ID NO:2.

6. (original) An isolated polypeptide comprising a sequence of amino acid residues that is at least 95% identical to residues 32 (Gln) to 162 (Ser) as shown in SEQ ID NO:2.

7. (canceled).

8. (canceled)

Applicants: Novak et al.

Serial No.: 10/659,684

Filed: September 10, 2003

For: CYTOKINE ZALPHA11 LIGAND

9. (currently amended) A pharmaceutical composition comprising a polypeptide comprising a sequence of amino acid residues that is at least 90% identical to residues 32 (Gln) to 162 (Ser) as shown in SEQ ID NO:2 in a pharmaceutically acceptable vehicle.

10. (currently amended) A pharmaceutical composition comprising a polypeptide comprising a sequence of amino acid residues that is at least 95% identical to residues 32 (Gln) to 162 (Ser) as shown in SEQ ID NO:2, in a pharmaceutically acceptable vehicle.

11. (currently amended) A pharmaceutical composition comprising a ~~polypeptide comprising~~ sequence of amino acid residues from residues 32 (Gln) to 162 (Ser) as shown in SEQ ID NO:2, in a pharmaceutically acceptable vehicle.

Claims 12-47 (canceled)